HC Wainwright & Co. Maintains Buy on ADC Therapeutics, Raises Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on ADC Therapeutics (NYSE:ADCT) and increased the price target from $3 to $9. This adjustment reflects a positive outlook on the company's future performance.
February 20, 2024 | 12:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reaffirmed a Buy rating on ADC Therapeutics and raised the price target from $3 to $9, indicating a strong positive outlook on the company's performance.
The significant increase in the price target from $3 to $9 by a reputable analyst firm like HC Wainwright & Co. suggests a strong conviction in ADC Therapeutics' potential for growth. This endorsement is likely to instill confidence among investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100